India, April 10 -- Drug major Johnson & Johnson (JNJ) on Tursday announced positive Icotrokinra results, which showed that 75% of adolescents with plaque psoriasis or PsO achieved completely clear skin and demonstrated favorable safety profile in a once daily pill.
The company revealed the new icotrokinra (JNJ-2113) data from a subgroup analysis of ICONIC-LEAD, the first ever Phase 3 registrational study in moderate-to-severe PsO to assess efficacy and safety of a systemic therapy in adolescents and adults simultaneously.
PsO is a chronic immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful.
Icotrokinra is a first-in-class investigational targeted oral peptid...